Section 08.64.367 - Use of amygdalin (laetrile)(a) A physician may not be subject to disciplinary action by the board for prescribing or administering amygdalin (laetrile) to a patient under the physician's care who has requested the substance unless the board in a hearing conducted under AS 44.62 (Administrative Procedure Act) has made a formal finding that the substance is harmful.(b) A hospital or health facility may not interfere with the physician-patient relationship by restricting or forbidding the use of amygdalin (laetrile) when prescribed or administered by a physician and requested by a patient unless the substance as prescribed or administered by the physician is found to be harmful by the board in a hearing conducted under the provisions of AS 44.62 (Administrative Procedure Act).(c) A physician may not be subject to disciplinary action by the board for prescribing, dispensing, or administering an investigational drug, biological product, or device, or providing related treatment, to a patient for the purpose of sustaining the patient's life if the patient(1) has a terminal illness;(2) is ineligible or unable to participate in a current clinical trial for the investigational drug, biological product, or device;(3) has considered, after consultation with the physician, all other treatment options currently approved by the United States Food and Drug Administration; and(4) has given informed consent in writing for the use of the investigational drug, biological product, or device.(d) In this section, (1) "investigational drug, biological product, or device" means a drug, biological product, or device that has successfully completed Phase 1 studies of clinical trials for investigation and remains in ongoing clinical trials under Phase 2 or Phase 3 or is in the new drug application process following Phase 3 of clinical trials, but has not been approved for general use by the United States Food and Drug Administration;(2) "terminal illness" means a disease that, without life-sustaining procedures, will result in death in the near future or a state of permanent unconsciousness from which recovery is unlikely.Amended by SLA 2018, ch. 53,sec. 1, eff. 10/11/2018.